Handgrip StrengthNCT07289698
Handgrip Strength Increases the Pressure in the Portal and Left Gastric Veins in Cirrhotic Patients
An observational study of Handgrip Strength and Transjugular Intrahepatic Portosystemic Shunts (TIPS), run by Shanxi Provincial People's Hospital at 2 sites in China.
Trial summary
1.Background Handgrip strength , a core indicator of muscle function, has been confirmed to be significantly associated with the clinical prognosis of patients with liver cirrhosis. However, no studies have explored its correlation with portal venous hemodynamics. 2. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Handgrip Strength, Transjugular Intrahepatic Portosystemic Shunts (TIPS)
- What is being tested?
- Handgrip strength
- Type of treatment
- Medical device
- How many people
- 64 participants
- Where
- 2 sitesChina
- Study dates
- 31 Dec 2025to 2 Apr 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: This observational study was performed in two centers in China (The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology [Luoyang], and Shanxi Provincial People's Hospital [Taiyuan]) . They serve as the major tertiary referral center for the management of liver cirrhosis and its complications in our country.
Who may be able to join
- adult patients (≥18 years of age) with cirrhosis and a history of variceal bleeding, who were preparing for TIPS creation for secondary prophylaxis against variceal bleeding
Who cannot join
- Severe congestive heart failure, or severe untreated valvular heart disease
- Moderate to severe pulmonary hypertension
- Uncontrolled systemic infection
- Lesions (e.g., cysts) or tumors in the liver parenchyma that preclude TIPS creation
- Overt hepatic encephalopathy
- Unrelieved biliary obstruction
Show all 11Show fewer
- Child-Pugh score > 13
- Model for end-stage liver disease (MELD) score > 18
- International normalized ratio (INR) > 5
- Platelet count < 20×109/mm3
- Participants who had undergone hand or wrist surgery within the previous 3 months or were unable to hold the dynamometer with the testing hand were excluded from the study.
Trial locations and contacts
2 sites in 1 country.
China2 sites
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, 471003
Shanxi Provincial People's Hospital
Taiyuan, Shanxi, 030012
About this study
1.Background Handgrip strength , a core indicator of muscle function, has been confirmed to be significantly associated with the clinical prognosis of patients with liver cirrhosis. However, no studies have explored its correlation with portal venous hemodynamics. 2. Objective The purpose of the study is to examine the effects of Handgrip strength on portal vein and left gastric vein pressure, blood flow velocity and direction in patients with liver cirrhosis.
- Method: observational study. Detection Timing: Doppler ultrasound was employed to determine the portal flow velocity and direction at baseline and during the handgrip strength test in cirrhotic patients with a history of variceal bleeding. Three days later, prior to TIPS placement, the pressures in the portal pressure and gastric vein pressure were measured both before and after handgrip strength. Furthermore, carvedilol and vasoactive drugs were discontinued three days before the study commenced. 4. Elaboration of the Research Hypothesis 4.1. Core Hypothesis The handgrip strength level in patients with liver cirrhosis is correlated with portal venous system hemodynamic indices. Specifically, enhanced handgrip strength may affect portal hypertension and the hemodynamics of varicose veins by improving systemic muscle function or circulatory status. 4.2. Speculation on potential mechanisms Association between muscle function and circulation: As a representative of systemic muscle function, increased handgrip strength may reflect an increase in cardiac output or changes in splanchnic vascular resistance, thereby influencing portal venous hemodynamics.
- Being tested
- Handgrip strength
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Handgrip strengthDevice
Jamar Hand Dynamometer, from Illinois, USA. Maximum handgrip strength was measured three times, with each measurement lasting 3 seconds and a 1-minute interval between tests
| Study group | Role | What they receive |
|---|---|---|
| Portal pressure measurement group | Not described Receives: Device: Handgrip strength | |
| Doppler Ultrasound Measurement Group | Not described Receives: Device: Handgrip strength |
What is being measured
The primary outcome is the main question the study is designed to answer.
portal pressure
Prior to TIPS, the pressure monitoring catheter was connected to the pressure-measuring device. Subsequently, the pressures in both the portal vein and left gastric vein were measured simultaneously at baseline and during the handgrip strength test.
Measured: through study completion, an average of 5 minutes
left gastric vein pressure
Prior to TIPS, the pressure monitoring catheter was connected to the pressure-measuring device. Subsequently, the pressures in both the portal vein and left gastric vein were measured simultaneously at baseline and during the handgrip strength test.
Measured: through study completion, an average of 5 minutes
portal flow velocity
Measured: At least 72 hours after the baseline handgrip strength and during the handgrip strength phase, measurements were conducted at intervals of 15 seconds, 30 seconds, 45 seconds, and 60 seconds after the release of strength related to the handgrip Strength
Portal vein blood flow direction
Measured: At least 72 hours after the baseline handgrip strength and during the handgrip strength phase, measurements were conducted at intervals of 15 seconds, 30 seconds, 45 seconds, and 60 seconds after the release of strength related to the handgrip Strength
Secondary outcomes (25)
Serum albumin (g / l)
Pre-TIPS baseline characteristics ,date (n=32)
Measured: Baseline
alanine aminotransferase(IU / L)
Pre-TIPS baseline characteristics, date (n=32)
Measured: Baseline
aspartate aminotransferase (IU / L)
Pre-TIPS baseline characteristics ,date (n=32)
Measured: Baseline
Total bilirubin (µmol / l)
Pre-TIPS baseline characteristics ,date (n=32)
Measured: Baseline
Prothrombin time (second)
Pre-TIPS baseline characteristics ,date (n=32)
Measured: Baseline
Fasting blood glucose (mmol / l)
Pre-TIPS baseline characteristics ,date (n=32)
Measured: Baseline
triglyceride (mmol / l)
Pre-TIPS baseline characteristics ,date (n=32)
Measured: Baseline
Total cholesterol (mmol / l)
Pre-TIPS baseline characteristics ,date (n=32)
Measured: Baseline
Serum creatinine (µmol / l)
Pre-TIPS baseline characteristics ,date (n=32)
Measured: Baseline
Serum potassium (mmol / l)
Pre-TIPS baseline characteristics ,date (n=32)
Measured: Baseline
Serum sodium (mmol / l)
Pre-TIPS baseline characteristics ,date (n=32)
Measured: Baseline
Serum chloride (mmol / l)
Pre-TIPS baseline characteristics ,date (n=32)
Measured: Baseline
Platelet count (× 109 / mm3)
Pre-TIPS baseline characteristics ,date (n=32)
Measured: Baseline
height
Measured: Baseline
weight
Measured: Baseline
Model for end-stage liver disease score
Model for end-stage liver disease score: 6-40, the higher scores mean a worse outcome.
Measured: Baseline
Child-Pugh score
Child-Pugh score: 5-15, the higher scores mean a worse outcome
Measured: Baseline
Esophageal varices before endoscopic treatment
The diagnosis of esophageal varices and variceal bleeding in patients is confirmed by upper gastrointestinal endoscopy.
Measured: Baseline
Collateral vessels before TIPS placement
Vascular angiography was performed prior to TIPS placement to diagnose collateral circulation. date (n=32)
Measured: Baseline
Ascites
Prior to TIPS, ascites was evaluated by ultrasound in 32 patients with liver cirrhosis.
Measured: Baseline
Prior overt hepatic encephalopathy
Measured: Baseline
Etiology of cirrhosis
Measured: Baseline
Age
Measured: Baseline
Sex
Measured: Baseline
Handgrip Strength
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Dec 2025
- Study start31 Dec 2025
- Primary completion2 Apr 2026
- Study completion2 Apr 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Handgrip StrengthStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 64 participants (actual)
Sponsor and investigators
- Lead sponsor
- Shanxi Provincial People's Hospital
- Sponsor type
- Other government
- Collaborators
- The First Affiliated Hospital of Henan University of Science and Technology
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07289698
- Sponsor's protocol ID
- MZ
- Status last verified
- Nov 2025
- First submitted
- 4 Dec 2025
- Last updated
- 6 Apr 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The way of sharing IPD: Sharing and email consultation will begin after December 31, 2027. Data collection and Management: Case record forms and electronic data captures.
Study at a glance
From the registry record, last updated by the sponsor on 6 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Handgrip Strength Increases the Pressure in the Portal and Left Gastric Veins in Cirrhotic Patients
- ClinicalTrials.gov ID
- NCT07289698
- Acronym / sponsor ID
- MZ
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 64 participants (actual)
- Lead sponsor
- Shanxi Provincial People's HospitalOther government
- Collaborators
- The First Affiliated Hospital of Henan University of Science and Technology
- Study start
- 31 Dec 2025 (actual)
- Primary completion
- 2 Apr 2026 (actual)
- Study completion
- 2 Apr 2026 (actual)
- First posted
- 17 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
1.Background Handgrip strength , a core indicator of muscle function, has been confirmed to be significantly associated with the clinical prognosis of patients with liver cirrhosis. However, no studies have explored its correlation with portal venous hemodynamics. 2. Objective The purpose of the study is to examine the effects of Handgrip strength on portal vein and left gastric vein pressure, blood flow velocity and direction in patients with liver cirrhosis.
- Method: observational study. Detection Timing: Doppler ultrasound was employed to determine the portal flow velocity and direction at baseline and during the handgrip strength test in cirrhotic patients with a history of variceal bleeding. Three days later, prior to TIPS placement, the pressures in the portal pressure and gastric vein pressure were measured both before and after handgrip strength. Furthermore, carvedilol and vasoactive drugs were discontinued three days before the study commenced. 4. Elaboration of the Research Hypothesis 4.1. Core Hypothesis The handgrip strength level in patients with liver cirrhosis is correlated with portal venous system hemodynamic indices. Specifically, enhanced handgrip strength may affect portal hypertension and the hemodynamics of varicose veins by improving systemic muscle function or circulatory status. 4.2. Speculation on potential mechanisms Association between muscle function and circulation: As a representative of systemic muscle function, increased handgrip strength may reflect an increase in cardiac output or changes in splanchnic vascular resistance, thereby influencing portal venous hemodynamics.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Portal pressure measurement group | – | Device: Handgrip strength |
| Doppler Ultrasound Measurement Group | – | Device: Handgrip strength |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- This observational study was performed in two centers in China (The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology [Luoyang], and Shanxi Provincial People's Hospital [Taiyuan]) . They serve as the major tertiary referral center for the management of liver cirrhosis and its complications in our country.
Key inclusion criteria (1 listed)
- adult patients (≥18 years of age) with cirrhosis and a history of variceal bleeding, who were preparing for TIPS creation for secondary prophylaxis against variceal bleeding
Key exclusion criteria (11 listed)
- Severe congestive heart failure, or severe untreated valvular heart disease
- Moderate to severe pulmonary hypertension
- Uncontrolled systemic infection
- Lesions (e.g., cysts) or tumors in the liver parenchyma that preclude TIPS creation
- Overt hepatic encephalopathy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Handgrip strengthJamar Hand Dynamometer, from Illinois, USA. Maximum handgrip strength was measured three times, with each measurement lasting 3 seconds and a 1-minute interval between tests | Device | Doppler Ultrasound Measurement Group, Portal pressure measurement group |
Primary outcome
portal pressure
Time frame: through study completion, an average of 5 minutes
Prior to TIPS, the pressure monitoring catheter was connected to the pressure-measuring device. Subsequently, the pressures in both the portal vein and left gastric vein were measured simultaneously at baseline and during the handgrip strength test.
left gastric vein pressure
Time frame: through study completion, an average of 5 minutes
Prior to TIPS, the pressure monitoring catheter was connected to the pressure-measuring device. Subsequently, the pressures in both the portal vein and left gastric vein were measured simultaneously at baseline and during the handgrip strength test.
portal flow velocity
Time frame: At least 72 hours after the baseline handgrip strength and during the handgrip strength phase, measurements were conducted at intervals of 15 seconds, 30 seconds, 45 seconds, and 60 seconds after the release of strength related to the handgrip Strength
Portal vein blood flow direction
Time frame: At least 72 hours after the baseline handgrip strength and during the handgrip strength phase, measurements were conducted at intervals of 15 seconds, 30 seconds, 45 seconds, and 60 seconds after the release of strength related to the handgrip Strength
25 secondary outcomes
Serum albumin (g / l)
Time frame: Baseline
alanine aminotransferase(IU / L)
Time frame: Baseline
aspartate aminotransferase (IU / L)
Time frame: Baseline
Total bilirubin (µmol / l)
Time frame: Baseline
Prothrombin time (second)
Time frame: Baseline
Fasting blood glucose (mmol / l)
Time frame: Baseline
triglyceride (mmol / l)
Time frame: Baseline
Total cholesterol (mmol / l)
Time frame: Baseline
Serum creatinine (µmol / l)
Time frame: Baseline
Serum potassium (mmol / l)
Time frame: Baseline
Serum sodium (mmol / l)
Time frame: Baseline
Serum chloride (mmol / l)
Time frame: Baseline
Platelet count (× 109 / mm3)
Time frame: Baseline
height
Time frame: Baseline
weight
Time frame: Baseline
Model for end-stage liver disease score
Time frame: Baseline
Child-Pugh score
Time frame: Baseline
Esophageal varices before endoscopic treatment
Time frame: Baseline
Collateral vessels before TIPS placement
Time frame: Baseline
Ascites
Time frame: Baseline
Prior overt hepatic encephalopathy
Time frame: Baseline
Etiology of cirrhosis
Time frame: Baseline
Age
Time frame: Baseline
Sex
Time frame: Baseline
Handgrip Strength
Time frame: Baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Apr 2026.
- Individual participant dataSharing planned: Yes. The way of sharing IPD: Sharing and email consultation will begin after December 31, 2027. Data collection and Management: Case record forms and electronic data captures.
Related trials for Handgrip Strength
Not yet recruitingObservational study
Preoperative Frailty and Suboptimal Mask Ventilation in Cardiac Surgery Patients
Frailty, Suboptimal Mask Ventilation
Active, not recruitingPhase 2
TCM Formula vs. HMB in Pre-Frail Elders: Muscle Strength and Bone Status
Pre-Frailty, Sarcopenia
Not yet recruiting
Effect of HMB Supplementation and Vivifrail Exercise on Body Composition, Handgrip Strength and Physical Performance in Women Over 60 Years of Age
Aging, Muscle Strength
RecruitingObservational study
Frailty and Ultrasound-Guided Central Venous Catheterization Difficulty in Adult Cardiac Surgery Patients
Frailty, Cardiac Surgery
Not yet recruiting
Effects of Supervised Aerobic Exercise on Biomarkers in Patients With nSCLC Receiving Immunotherapy
Non-Small Cell Lung Cancer, Aerobic Exercise
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Handgrip Strength and Transjugular Intrahepatic Portosystemic Shunts (TIPS), run by Shanxi Provincial People's Hospital at 2 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
portal pressure (time frame: through study completion, an average of 5 minutes). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Apr 2026.